Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-4 PE38KDEL cytotoxin
- Development stage
- Unknown
- Lead developer
- Neurocrine Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Intratumoral Infusion
01
Overview
Interleukin-4 PE38KDEL cytotoxin is a recombinant fusion protein designed as a targeted therapy for cancers that overexpress interleukin-4 receptors (IL-4R). It is composed of a circularly permuted human interleukin-4 (IL-4) component fused to a truncated form of Pseudomonas exotoxin (PE38KDEL). The IL-4 portion specifically binds to IL-4R on cancer cells, facilitating the internalization of the fusion protein. Once inside the cell, the PE38KDEL component, which consists of specific amino acid sequences from Pseudomonas exotoxin, inhibits protein synthesis by ADP ribosylation of elongation factor 2, leading to apoptosis of the cancer cell. This mechanism allows for selective targeting of tumor cells while sparing normal cells that express low or no IL-4R. The drug was developed by Neurocrine Biosciences and produced by Inland Labs.
- Other names
- IL-4-toxinIL4-toxinIL 4-toxin
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on interleukin-4 PE38KDEL cytotoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-4 PE38KDEL cytotoxin.